Separation of bispecific antibodies and bispecific antibody production side products using hydroxyapatite chromatography

Patent metadata

Field	Value
Publication number	US-10316059-B2
Application number	US-201615048308-A
Country	US
Kind code	B2
Filing date	Feb 19, 2016
Priority date	Aug 19, 2013
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

The present invention is directed to methods comprising the use of hydroxyapatite chromatography to separate a bispecific antibody from a solution that also comprises one or more byproducts specific to bispecific antibody production. Byproducts specific to the production of bispecific antibodies (bispecific antibody specific byproducts, “BASB”) include fragments of the bispecific antibody and heavier molecular weight variants of the antibody, wherein the fragment and/or variant comprises an Fc domain but does not exhibit affinity for the two different epitopes and/or antigens as exhibited by the desired bispecific antibody. Thus, the methods of the present invention comprise the separation of a bispecific antibody from one or more of its BASB. The hydroxyapatite chromatography methods of the invention may be used alone or may be further combined with standard purification processes and unit operations as is known in the art to achieve any level of purity of bispecific antibody necessary, e.g., for therapeutic and/or diagnostic applications.

First claim

The invention claimed is:

1. A method of separating a bispecific antibody comprising an Fc domain from a solution comprising said bispecific antibody, said method comprising
(a) contacting said solution with a hydroxyapatite chromatography medium,
wherein said solution further comprises
(i) one or more fragments of said bispecific antibody, which one or more fragments comprise an Fc domain, and/or
(ii) one or more bispecific antibody specific byproducts (BASBs) having a heterodimer or homodimer of antibody heavy chains, a single antibody light chain and a Fab or scFab fragment, which one or more BASBs comprise an Fc domain;

(b) adsorbing said bispecific antibodies to said hydroxyapatite chromatography medium, and
(c) eluting said bispecific antibody from said hydroxyapatite chromatography medium in the presence of chloride ions,

wherein said eluting comprises
(i) a starting composition of elution buffer having a pH of 6.5 to 8.0, a phosphate ion concentration of between about 1 mM and about 20 mM, a calcium ion concentration of between about 0.001 mM and about 0.5 mM and a chloride ion concentration of between about 10 mM and about 200 mM
(ii) increasing the chloride ion concentration of said starting composition according to a gradient; and
(iii) obtaining an eluate fraction, which fraction contains said bispecific antibody but does not contain at least one of said one or more fragments and/or does not contain at least one of said one or more BASBs.

2. The method according to claim 1 , wherein said at least one of said one or more fragments is a ½ antibody or a ¾ antibody; or wherein said at least one of said one or more polypeptides is a 5/4 antibody.

3. The method according to claim 1 , wherein said eluting is in the presence of an elution buffer having a pH of 6.5 to 7.5, a phosphate ion concentration of about 10 mM, a calcium ion concentration of about 0.1 mM and a chloride ion concentration of 50 mM, wherein the concentration of chloride ions is increased in a gradient from about 50 mM to about 500 mM.

4. The method according to claim 3 , wherein said gradient is a linear gradient, a stepwise gradient, or a combination thereof in a linear-stepwise gradient.

5. The method according to claim 1 , wherein said solution comprises the bispecific antibody-containing fraction or pooled bispecific antibody containing fractions from the eluate of an affinity chromatography medium having specificity for at least one of an antibody Fc domain, a kappa domain of an antibody light chain, and a lambda domain of an antibody light chain.

6. The method according to claim 1 , wherein said method further comprises an upstream or downstream ion exchange chromatography process, which process separates said bispecific antibody from at least one of said fragments, said polypeptides, and a ½ antibody homodimer.

7. The method according to claim 6 , wherein said ion exchange chromotography process is a cation exchange unit operation.

8. The method according to claim 1 , wherein said bispecific antibody is a CrossMab bispecific antibody or wherein one of the heavy chains of said bispecific antibody comprises a scFab.

9. The method according to claim 1 , wherein said bispecific antibody is a knob-in-hole (KiH) bispecific antibody.

10. The method according to claim 1 , wherein said bispecific antibody is a CrossMab and KiH bispecific antibody, and wherein said bispecific antibody has specificity for EGFR and IGFR, or has specificity for Ang2 and VEGF.

11. The method according to claim 1 , wherein one of the heavy chains of said bispecific antibody comprises a scFab, wherein said bispecific antibody is a KiH bispecific antibody, and wherein said bispecific antibody has specificity for the combination of
Ang2 and VEGF,
EGFR and IGFR, or
TWEAK and IL17.

Assignees

• Hoffmann La Roche

Inventors

• Bertl Sabine
• Duerr Harald
• Schaubmar Andreas

Classifications

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• C07K16/2875

  against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• B01D15/362 Primary

  Cation-exchange · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title